Michel Willemsen, MD, PhD and his colleagues at Radboud University in the Netherlands have begun an “open-label” clinical trial of nicotinamide riboside in children and young adults with ataxia telangiectasia (A-T). With financial support from the A-T Children’s Project, Dr. Willemsen’s team is currently enrolling 32 individuals with A-T in the Netherlands in a four-month clinical study to test the dietary supplement, brand named Niagen®, which is a form of vitamin B3.

Several researchers have previously reported that vitamin B3 metabolism is abnormal in cell and small animal models of A-T, while others have found that treating those models with nicotinamide riboside corrects some of the abnormalities associated with A-T. There have also been a handful of case reports in which families and physicians have believed that their A-T children had more energy and muscle control when taking nicotinamide riboside.

The current trial is intended to be exploratory, looking for clinical effects and changes in laboratory markers, but recognizing that it will not be a placebo-controlled, blinded study. If nicotinamide riboside appears to change certain blood parameters, motor performance tasks, speech patterns or overall quality of life for patients with A-T, the A-T Children’s Project will then consider supporting a more formal, placebo-controlled, double-blinded, cross-over trial of this product in a larger number of patients to obtain a definitive, conclusive evaluation of nicotinamide riboside’s efficacy in A-T.

Contact Us

Related News

Mar 3 @ 1:06 am

Looking Forward to Research Advances in 2024

Dear Friends, As 2023 is wrapping up, we want to thank all of you who support the A-T…

more
Mar 3 @ 1:06 am

A-T Biomarker Development Initiative Now Recruiting

On December 18, the A-T Children’s Project sent out the below email to A-T parents in the United…

more
Mar 3 @ 1:06 am

A-T Caregiver Weekend 2024 Announced

On December 15, the A-T Children’s Project sent the below email to parents inviting them to join us…

more
Mar 3 @ 1:06 am

Giving Tuesday Update 2023

It’s Giving Tuesday, and anonymous donors have joined together to match the first $60,000 in donations we receive!

more